The FDA approved updated COVID-19 vaccines that target a newer branch of omicron descendants.

The Covid jabs target a strain called KP.2, a descendant of the highly contagious omicron subvariant JN.1 that began circulating widely in the U.S. this year.

The Biden administration said it expects the new Pfizer and Moderna vaccines targeting the omicron variant XBB.1.5 to be available in mid-September. 

Multiple mutations of the omicron COVID-19 variant are making their way through the United States, but what do we know about these new strains?

Officials are already expecting updated COVID-19 vaccines that contain one version of the omicron strain, called XBB.1.5.

Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.

The drugmakers designed their updated coronavirus shots to target the omicron subvariant XBB.1.5, which is slowly declining nationwide.

Pfizer, Moderna and Novavax are slated to deliver new single-strain Covid shots targeting the omicron subvariant XBB.1.5 in September.

Pfizer, Moderna and Novavax have not disclosed the exact pricing of their new vaccines, which will target the circulating omicron subvariant XBB.1.5. 

Moderna said the submission is based on the FDA’s recommendation that vaccine makers update their jabs to target omicron subvariant XBB.1.5.